Combined Low Dose of Ketamine and Social Isolation: A Possible Model of Induced Chronic Schizophrenia-Like Symptoms in Male Albino Rats.
ketamine
rat
schizophrenia
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
11 Jul 2021
11 Jul 2021
Historique:
received:
22
03
2021
revised:
05
07
2021
accepted:
08
07
2021
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
7
8
2021
Statut:
epublish
Résumé
While animal models for schizophrenia, ranging from pharmacological models to lesions and genetic models, are available, they usually mimic only the positive symptoms of this disorder. Identifying a feasible model of chronic schizophrenia would be valuable for studying the possible underlying mechanism and to investigate emerging treatments. Our hypothesis starts from the observation that combining ketamine with isolation could result in long-lasting neuro-psychological deficits and schizophrenia-like features; thus, it could probably be used as the first model of chronic schizophrenia that emphasizes the characteristic of having a multifactorial etiology. By the means of this study, we investigated the effects of ketamine administration combined with isolation in inducing schizophrenia-like symptoms in male albino rats and the brain reactive oxygen species levels. Our results showed that the number of lines crossings in the open field test, the number of open arm entries in the elevated plus maze, and the spontaneous alternations percentage in the Y-maze were significantly lower in the ketamine + isolation group compared to both the control and ketamine + social housing group (
Identifiants
pubmed: 34356151
pii: brainsci11070917
doi: 10.3390/brainsci11070917
pmc: PMC8303272
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Neurosci Lett. 2010 Aug 2;479(3):317-20
pubmed: 20561936
Psychopharmacology (Berl). 2005 Apr;179(1):303-9
pubmed: 15309376
Cogn Behav Neurol. 2006 Sep;19(3):150-6
pubmed: 16957493
Biol Psychiatry. 2004 Sep 1;56(5):317-22
pubmed: 15336513
J Psychopharmacol. 2004 Sep;18(3):375-83
pubmed: 15358981
Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14731-6
pubmed: 11121072
J Psychopharmacol. 2007 May;21(3):338-46
pubmed: 17591660
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Oct 1;32(7):1677-81
pubmed: 18657586
Schizophr Res. 1996 Mar;19(1):19-26
pubmed: 9147492
J Psychiatr Res. 2015 Feb;61:64-72
pubmed: 25560772
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):310-6
pubmed: 22561603
Biochem Soc Trans. 1997 Aug;25(3):418S
pubmed: 9388648
Curr Top Med Chem. 2006;6(8):771-85
pubmed: 16719816
J Clin Psychopharmacol. 2003 Apr;23(2):128-31
pubmed: 12640213
J Psychiatr Res. 1998 Nov-Dec;32(6):385-91
pubmed: 9844955
Brain Res Brain Res Rev. 1995 Feb;20(2):250-67
pubmed: 7795658
Br J Pharmacol. 2011 Oct;164(4):1162-94
pubmed: 21449915
J Lab Clin Med. 1967 Jul;70(1):158-69
pubmed: 6066618
PLoS One. 2013;8(2):e56053
pubmed: 23390559
Handb Exp Pharmacol. 2008;(182):313-33
pubmed: 18175098
Neuropsychopharmacology. 1998 Nov;19(5):434-44
pubmed: 9778665
Annu Rev Pharmacol Toxicol. 2002;42:165-79
pubmed: 11807169
Psychiatry Res. 2003 Dec 1;121(2):109-22
pubmed: 14656446
BMC Genomics. 2006 Apr 04;7:70
pubmed: 16594998
Nat Protoc. 2007;2(2):322-8
pubmed: 17406592
J Biol Chem. 1972 May 25;247(10):3170-5
pubmed: 4623845
Neuroscience. 2004;126(3):591-8
pubmed: 15183509
Schizophr Res. 2009 May;110(1-3):1-23
pubmed: 19328655
Psychiatry Res. 2003 Jan 25;117(1):85-8
pubmed: 12581823
BMC Psychiatry. 2014 Jun 05;14:166
pubmed: 24903304
Neuropsychopharmacology. 1995 Aug;13(1):9-19
pubmed: 8526975
Psychopharmacology (Berl). 2006 May;186(1):64-81
pubmed: 16550385
Nat Rev Drug Discov. 2008 Jan;7(1):68-83
pubmed: 18064038
Psychopharmacology (Berl). 2001 Nov;158(2):140-5
pubmed: 11702087
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Dec;28(8):1267-77
pubmed: 15588753
Eur Neuropsychopharmacol. 2014 May;24(5):759-73
pubmed: 24342774
BMC Neurosci. 2015 Mar 07;16:9
pubmed: 25887360
Neuroreport. 2017 May 24;28(8):462-469
pubmed: 28410269
Neurobiol Dis. 2013 Nov;59:126-40
pubmed: 23891727
Addiction. 2010 Jan;105(1):121-33
pubmed: 19919593
Transl Psychiatry. 2017 Sep 19;7(9):e1237
pubmed: 28926001
Singapore Med J. 2003 Aug;44(8):391-6
pubmed: 14700417
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Oct 1;33(7):1178-83
pubmed: 19576938
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Jun;27(4):687-700
pubmed: 12787858
Schizophr Res. 2011 Feb;125(2-3):143-51
pubmed: 21112743
Brain Res Bull. 2009 Aug 14;79(6):418-21
pubmed: 19393724
Lancet. 1995 Aug 19;346(8973):477-81
pubmed: 7637483
Curr Neuropharmacol. 2014 Mar;12(2):140-7
pubmed: 24669208
Neuropsychopharmacology. 2001 Oct;25(4):455-67
pubmed: 11557159
Neurobiol Dis. 2009 Aug;35(2):311-7
pubmed: 19467327
Mol Psychiatry. 2017 Jul;22(7):936-943
pubmed: 28322275
Eur Neuropsychopharmacol. 2010 Jan;20(1):37-48
pubmed: 19729284
Vet Anaesth Analg. 2009 Jul;36(4):319-27
pubmed: 19470142
J Psychopharmacol. 2014 Apr;28(4):287-302
pubmed: 24257811
Pharmacol Biochem Behav. 1997 Dec;58(4):1031-6
pubmed: 9408210
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):155-9
pubmed: 17804133
Addiction. 2012 Jan;107(1):27-38
pubmed: 21777321
Curr Drug Saf. 2012 Apr;7(2):106-19
pubmed: 22873495
Neuropsychopharmacology. 2011 Dec;36(13):2774-81
pubmed: 21956441
Oxid Med Cell Longev. 2010 Nov-Dec;3(6):421-7
pubmed: 21270541
Neuropsychopharmacology. 2006 Sep;31(9):1854-63
pubmed: 16319908